Logo image of CGEM

CULLINAN THERAPEUTICS INC (CGEM) Stock Price, Quote, News and Overview

NASDAQ:CGEM - Nasdaq - US2300311063 - Common Stock - Currency: USD

7.9  +0.15 (+1.87%)

After market: 7.9 0 (0%)

CGEM Quote, Performance and Key Statistics

CULLINAN THERAPEUTICS INC

NASDAQ:CGEM (4/29/2025, 4:30:01 PM)

After market: 7.9 0 (0%)

7.9

+0.15 (+1.87%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High30.19
52 Week Low6.85
Market Cap462.23M
Shares58.51M
Float51.08M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-20 2025-05-20/bmo
IPO01-08 2021-01-08


CGEM short term performance overview.The bars show the price performance of CGEM in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30 -40

CGEM long term performance overview.The bars show the price performance of CGEM in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of CGEM is 7.9 USD. In the past month the price increased by 4.36%. In the past year, price decreased by -72.13%.

CULLINAN THERAPEUTICS INC / CGEM Daily stock chart

CGEM Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.84 342.32B
AMGN AMGEN INC 14.56 155.14B
GILD GILEAD SCIENCES INC 13.46 129.91B
VRTX VERTEX PHARMACEUTICALS INC 1736.21 129.44B
REGN REGENERON PHARMACEUTICALS 12.47 62.19B
ARGX ARGENX SE - ADR 331.32 38.44B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.46B
ONC BEIGENE LTD-ADR N/A 26.92B
BNTX BIONTECH SE-ADR N/A 25.00B
NTRA NATERA INC N/A 20.94B
BIIB BIOGEN INC 7.3 17.59B
SMMT SUMMIT THERAPEUTICS INC N/A 17.42B

About CGEM

Company Profile

CGEM logo image Cullinan Therapeutics, Inc. is a biopharmaceutical company engaged in developing oncology and immuno-oncology therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 111 full-time employees. The company went IPO on 2021-01-08. The company has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.

Company Info

CULLINAN THERAPEUTICS INC

One Main Street, Suite 1350

Cambridge MASSACHUSETTS 02142 US

CEO: Owen Hughes

Employees: 111

Company Website: https://cullinantherapeutics.com/

Investor Relations: http://cullinanoncology.com/investors-overview/

Phone: 16174104650

CULLINAN THERAPEUTICS INC / CGEM FAQ

What is the stock price of CULLINAN THERAPEUTICS INC today?

The current stock price of CGEM is 7.9 USD. The price increased by 1.87% in the last trading session.


What is the ticker symbol for CULLINAN THERAPEUTICS INC stock?

The exchange symbol of CULLINAN THERAPEUTICS INC is CGEM and it is listed on the Nasdaq exchange.


On which exchange is CGEM stock listed?

CGEM stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CULLINAN THERAPEUTICS INC stock?

16 analysts have analysed CGEM and the average price target is 32.81 USD. This implies a price increase of 315.32% is expected in the next year compared to the current price of 7.9. Check the CULLINAN THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CULLINAN THERAPEUTICS INC worth?

CULLINAN THERAPEUTICS INC (CGEM) has a market capitalization of 462.23M USD. This makes CGEM a Small Cap stock.


How many employees does CULLINAN THERAPEUTICS INC have?

CULLINAN THERAPEUTICS INC (CGEM) currently has 111 employees.


What are the support and resistance levels for CULLINAN THERAPEUTICS INC (CGEM) stock?

CULLINAN THERAPEUTICS INC (CGEM) has a resistance level at 8.01. Check the full technical report for a detailed analysis of CGEM support and resistance levels.


Should I buy CULLINAN THERAPEUTICS INC (CGEM) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CULLINAN THERAPEUTICS INC (CGEM) stock pay dividends?

CGEM does not pay a dividend.


When does CULLINAN THERAPEUTICS INC (CGEM) report earnings?

CULLINAN THERAPEUTICS INC (CGEM) will report earnings on 2025-05-20, before the market open.


What is the Price/Earnings (PE) ratio of CULLINAN THERAPEUTICS INC (CGEM)?

CULLINAN THERAPEUTICS INC (CGEM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.03).


What is the Short Interest ratio of CULLINAN THERAPEUTICS INC (CGEM) stock?

The outstanding short interest for CULLINAN THERAPEUTICS INC (CGEM) is 15.65% of its float. Check the ownership tab for more information on the CGEM short interest.


CGEM Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to CGEM. When comparing the yearly performance of all stocks, CGEM is a bad performer in the overall market: 92.99% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CGEM Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to CGEM. While CGEM has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CGEM Financial Highlights

Over the last trailing twelve months CGEM reported a non-GAAP Earnings per Share(EPS) of -3.03. The EPS increased by 17.89% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -26.92%
ROE -28.35%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-35.19%
Sales Q2Q%N/A
EPS 1Y (TTM)17.89%
Revenue 1Y (TTM)N/A

CGEM Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 88% to CGEM. The Buy consensus is the average rating of analysts ratings from 16 analysts.


Ownership
Inst Owners114.01%
Ins Owners0.86%
Short Float %15.65%
Short Ratio17.25
Analysts
Analysts87.5
Price Target32.81 (315.32%)
EPS Next Y-10.75%
Revenue Next YearN/A